MG1-MAGEA3

AXP000121.1 · Oncolytic virus

Platform
Maraba virus MG1 (double-mutant, recombinant)
Originator
Ottawa Hospital Research Institute (John Bell)
Sponsor
Turnstone Biologics

Names

NameTypeSource
MG1-MAGEA3preferred name, codecurator, ctgov
MG1MA3codencit
MG1 Maraba/MAGE-A3synonymncit

Virus

Role
Oncolytic
Family
Rhabdoviridae
Virus
Maraba virus (NCBI Taxonomy 1046251)
Strain
MG1 (G Q242R, M L123W)
Replication
replicating
Modifications
attenuating G and M mutations (MG1 backbone); MAGE-A3 transgene inserted
Transgenes
MAGEA3
Route
intravenous
Source
evidence

Cross-references

NCI Thesaurus
C118973

Approvals

No regulatory approval recorded.

Clinical trials (3)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03773744MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell CarcinomaWithdrawnPhase 12020-02-152020-10-300Metastatic Melanoma; Squamous Cell Skin Carcinoma
NCT02879760Oncolytic MG1-MAGEA3 With Ad-MAGEA3 Vaccine in Combination With Pembrolizumab for Non-Small Cell Lung Cancer PatientsCompletedPhase 1/22017-03-082020-02-1516Non-Small Cell Lung Cancer
NCT02285816MG1 Maraba/MAGE-A3, With and Without Adenovirus Vaccine With Transgenic MAGE-A3 Insertion in Incurable MAGE-A3-Expressing Solid TumoursActive not recruitingPhase 1/22015-01-222019-09-1956Advanced/Metastatic Solid Tumours

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 40389376Oncolytic VSV-IL-2 has enhanced anticancer vaccination adjuvant abilities.Journal for immunotherapy of cancer2025cited by trial NCT02285816
PMID 33608375In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.Journal for immunotherapy of cancer2021cited by trial NCT02285816
PMID 30546947Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.Oncoimmunology2019cited by trial NCT02285816

Notes

Maraba MG1 (G protein Q242R, M protein L123W) encoding MAGE-A3, given as a boost after an adenoviral Ad-MAGEA3 prime. Ad-MAGEA3 is a separate adenoviral construct and belongs to the adenovirus group, not entered here. Turnstone deprioritised the MG1 programme; NCT03773744 was withdrawn.

How to cite

MG1-MAGEA3 (AXP000121.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000121.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.